Presence and short‐term persistence of SARS‐CoV‐2 neutralizing antibodies in COVID‐19 convalescent plasma donors

BACKGROUND: In March 2020, the Food and Drug Administration (FDA) approved use of COVID‐19 convalescent plasma (CCP) as an investigational new drug for treatment of COVID‐19. Since then, collection of CCP from COVID‐19–recovered patients has been implemented in donor centers nationwide. Childrenʼs H...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Transfusion
Auteurs principaux: Annen, Kyle, Morrison, Thomas E., DomBourian, Melkon G., McCarthy, Mary K., Huey, Leah, Merkel, Patricia A., Andersen, Gillian, Schwartz, Eileen, Knight, Vijaya
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2021
Sujets:
Donor Infectious Disease Testing
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8014809/
https://ncbi.nlm.nih.gov/pubmed/33452828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/trf.16261
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires